RANI Stock Price, Chart, Stats & News

Rani Therapeutics Holdings, Inc.
Save
51.06M
Market cap
–
Current P/E
–
Forward P/E
RANI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 74.95% |
Operating margin | -2345.93% |
Pretax margin | -2507.65% |
Net margin | -1817.15% |
Effective tax rate | – |
ROA | -50.62% |
ROE | -718.54% |
D/E | 0.13x |
Interest coverage ratio | -13.25x |
RANI valuation
P/E | – |
P/S | 32.42x |
P/B | 3.61x |
P/CF | -6.37x |
P/FCF | -2.82x |
P/OCF | -6.37x |
PEG | -0.16x |
EV multiple | -1.81x |
About
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments.
Similar securities
Based on sector and market capitalization
Report issue











